What is CDLX's health score?

Cardlytics, Inc. (CDLX) has a TradeApes health score of 50 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CDLX's estimated fair value?

Based on our 5-year discounted cash flow model, Cardlytics, Inc.'s estimated fair value is $3.23 per share, representing a 471.4% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is CDLX undervalued or overvalued?

Our model currently rates CDLX as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CDLX... Refresh in a moment for the full analysis.

Cardlytics, Inc. (CDLX)

Technology Undervalued low mixed

$0.56

Updated: 2026-06-05

TradeApes Score

Financial Strength

65 Healthy

Operating Trend

30 Weak

Relative Value

65 Healthy

Capital Allocation

30 Weak

Risk

50 Mixed

Est. Fair Value $3.23

DCF Upside +471.4%

Sector Rank #4850 of 7693

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.